Nuzenio

Diabetic Macular Edema

Diabetic Macular Edema news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Infographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial - NatureNature · Fri, 07 Aug 2026 15:26:52 GMT Gout May Raise Risk of Diabetic Retinopathy Complications, Study Finds - Review of OptometryReview of Optometry · Fri, 07 Aug 2026 10:06:09 GMT Faricimab in the Treatment of Retinal Disease: A Narrative Review - CureusCureus · Fri, 07 Aug 2026 06:26:24 GMT Study Identifies OCT Biomarkers to Help Predict DME Treatment Response - Review of OptometryReview of Optometry · Mon, 03 Aug 2026 21:09:26 GMT EyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edema - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 31 Jul 2026 07:37:59 GMT EyePoint Completes Enrollment of Both Pivotal Phase 3 - GlobeNewswireGlobeNewswire · Thu, 30 Jul 2026 11:00:00 GMT EyePoint Completes Enrollment in Phase 3 Diabetic Macular Edema Trials - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 07:00:00 GMT Anti-VEGF/Ang-2 therapy shows fast drying in diabetic macular edema - HealioHealio · Wed, 29 Jul 2026 15:36:38 GMT

Timeline

Fri, 07 Aug 2026 15:26:52 GMTInfographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial - Nature

Fri, 07 Aug 2026 10:06:09 GMTGout May Raise Risk of Diabetic Retinopathy Complications, Study Finds - Review of Optometry

Fri, 07 Aug 2026 06:26:24 GMTFaricimab in the Treatment of Retinal Disease: A Narrative Review - Cureus

Mon, 03 Aug 2026 21:09:26 GMTStudy Identifies OCT Biomarkers to Help Predict DME Treatment Response - Review of Optometry

Fri, 31 Jul 2026 07:37:59 GMTEyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edema - The Clinical Trial Vanguard

Thu, 30 Jul 2026 11:00:00 GMTEyePoint Completes Enrollment of Both Pivotal Phase 3 - GlobeNewswire

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.

Connected entities

EyePoint Completes Enrollment3 live mentions Trials3 live mentions Efficacy2 live mentions PHOTON2 live mentions Diabetic Retinopathy Complications2 live mentions Review2 live mentions Optometry Review2 live mentions Optometry2 live mentions Treatment2 live mentions Retinal Disease2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Diabetic Macular Edema.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.